Cheng AL - Search Results

1

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Abou-Alfa GK, et al. Among authors: cheng al. N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002. N Engl J Med. 2018. PMID: 29972759 Free PMC article. Clinical Trial.

2

HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity.

Hsu C, Huang CL, Hsu HC, Lee PH, Wang SJ, Cheng AL. Hsu C, et al. Among authors: cheng al. Cancer. 2002 Jan 15;94(2):415-20. doi: 10.1002/cncr.10180. Cancer. 2002. PMID: 11900227 Free article.

3

Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.

Hsu C, Huang CS, Chao TY, Lu YS, Bu CF, Chen MM, Chang KJ, Cheng AL. Hsu C, et al. Among authors: cheng al. Cancer. 2002 Nov 15;95(10):2044-50. doi: 10.1002/cncr.10951. Cancer. 2002. PMID: 12412156 Free article. Clinical Trial.

4

Low-dose thalidomide treatment for advanced hepatocellular carcinoma.

Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Hsu C, et al. Among authors: cheng al. Oncology. 2003;65(3):242-9. doi: 10.1159/000074477. Oncology. 2003. PMID: 14657598

5

Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.

Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL. Lu YS, et al. Among authors: cheng al. Hepatogastroenterology. 2004 May-Jun;51(57):815-9. Hepatogastroenterology. 2004. PMID: 15143923 Clinical Trial.

6

Recent advances in non-surgical treatment for advanced hepatocellular carcinoma.

Hsu C, Cheng JC, Cheng AL. Hsu C, et al. Among authors: cheng al, cheng jc. J Formos Med Assoc. 2004 Jul;103(7):483-95. J Formos Med Assoc. 2004. PMID: 15318270 Review.

7

Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial.

Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Lin CC, et al. Among authors: cheng al. Invest New Drugs. 2007 Feb;25(1):77-84. doi: 10.1007/s10637-006-9004-9. Epub 2006 Aug 26. Invest New Drugs. 2007. PMID: 16937079 Clinical Trial.

8

Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment.

Lin ZZ, Hsu C, Chang YC, Yu CJ, Hsu CH, Lin CC, Cheng AL, Yang PC, Yang CH. Lin ZZ, et al. Among authors: cheng al. Lung Cancer. 2008 May;60(2):215-21. doi: 10.1016/j.lungcan.2007.10.002. Epub 2007 Nov 19. Lung Cancer. 2008. PMID: 18022277 Clinical Trial.

9

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Cheng AL, et al. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16. Lancet Oncol. 2009. PMID: 19095497 Clinical Trial.

10

Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients.

Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, Chen DS, Wang JD, Sheu JC. Chen CH, et al. Among authors: cheng al. Eur J Cancer. 2009 Jun;45(9):1630-9. doi: 10.1016/j.ejca.2008.12.025. Epub 2009 Jan 20. Eur J Cancer. 2009. PMID: 19157858

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

805 results

Search Page